New resource available view now
POTOMAC, MARYLAND – April 08, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage biotechnology company with its lead program currently in a Phase 2 CALMA clinical trial evaluating IGC-AD1 for Alzheimer’s-related agitation today announced that Ascendiant Capital Markets has
POTOMAC, MARYLAND – April 07, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage biotechnology company developing innovative treatments for Alzheimer’s disease, today announced the activation of a new clinical trial site
Strategic Pivot to Pure-Play Biotech
POTOMAC, Maryland – March 18, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage biotechnology company developing therapeutics for Alzheimer’s disease, today announced it will demonstrate its Agentic Harmonization Assistant
POTOMAC, MARYLAND – February 26, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage biotechnology company developing therapeutics for Alzheimer’s disease, today announced the filing
POTOMAC, MARYLAND – February 24, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), today announced that Ascendiant Capital Markets has issued an updated equity research report
– Practice integrated neurology network expands enrollment capacity –
POTOMAC, MARYLAND – February 17, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), today announced that the Canadian Intellectual Property Office (“CIPO”) has issued a Notice of Allowance covering the proprietary composition underlying IGC-AD1, the Company’s Phase 2 clinical stage program for agitation associated with Alzheimer’s disease. With this allowance, patent No. 3,095,729, titled “Method and Composition
POTOMAC, MARYLAND – February 12, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), today announced that CEO Ram Mukunda and CCO Claudia Grimaldi will be participating in a fireside chat hosted by Ascendiant Capital Markets on Wednesday, February 18, 2026, at 1:00 p.m. ET. IGC Pharma’s management will
POTOMAC, Maryland – February 09, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”) today announced the expansion of its Phase 2 CALMA trial for IGC-AD1 into Colombia, South America, through the addition of Grupo de Neurociencias de Antioquia (“GNA”). This expansion marks a pivotal operational milestone as IGC enters a region internationally recognized for its unique, genetically linked Alzheimer’s population. The GNA site is the latest addition to a